Heart-Saving hope for neuroendocrine cancer patients
NCT ID NCT04810091
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 30 times
Summary
This study tests whether adding telotristat ethyl to standard therapy can help control carcinoid syndrome and prevent heart damage in people with advanced neuroendocrine tumors that have spread. About 79 adults who are already on stable somatostatin analog therapy will take part. The main goal is to measure changes in a heart stress marker (NTproBNP) and walking ability over 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.